GC Biopharma, Sanofi to jointly market Plavix

GC will be responsible for the sales and marketing of the anti-platelet drug Plavix in S.Korea

Plavix
Plavix
Jung-Eun Kim 1
2023-02-13 16:27:36 likesmile@hankyung.com
Bio & Pharma

GC Biopharma Co. (formerly Green Cross Corp.) said on Monday it has entered into a joint sales partnership with Sanofi-Aventis Korea, the South Korean subsidiary of multinational pharmaceuticals company Sanofi, for Plavix 75 mg, an antiplatelet medication.

The agreement calls for GC Biopharma to take charge of the sales and marketing of Plavix, focusing primarily on domestic clinics.

Plavix is an antiplatelet drug prescribed for patients who have suffered a stroke, myocardial infarction or peripheral arterial disease.

"We are committed to continuing our cooperation with initiatives such as open innovation and joint sales partnerships to provide various treatment options for managing the risk factors of chronic diseases in Korea," said an official from GC Biopharma.

Write to Jung-Eun Kim at likesmile@hankyung.com
#GC Biopharma #Green Cross Corp #Sanofi #Sanofi-Aventis Korea #Plavix 75 mg #antiplatelet drug #gc korea sanofi #korea plavix gc-biopharma

GC Biopharma confirms safety of flu vaccine in phase 1 trial

GC Biopharma confirms safety of flu vaccine in phase 1 trial

GC Biopharma Hwasun plant South Korea's leading pharmaceutical company GC Biopharma Co. (Green Cross Corp.) said on Thursday that it has confirmed the safety and immunogenicity of the patch-type influenza vaccine MIMIX-Flu, which is under development jointly with Vaxess Technologies of the Unit

GC Biopharma's Sanfilippo treatment eligible for FDA priority review

GC Biopharma's Sanfilippo treatment eligible for FDA priority review

GC Biopharma headquarters  GC Biopharma Co. (Green Cross Corp.) said on Wednesday that its Sanfilippo type A treatment, which is under joint development with Novel Pharma, a bio-venture specializing in orphan drugs, has received rare pediatric disease designation (RPDD) from the US Food an

GC Biopharma's Ochang facility gets WHO PQ certification

GC Biopharma's Ochang facility gets WHO PQ certification

GC Biopharma GC Biopharma Co.'s production facility in Ochang (North Chungcheong Province) secured a pre-qualification (PQ) certification from the World Health Organization (WHO).According to the company formerly known as GC Green Cross on Thursday, the 'integrated finished product facility' in

Green Cross in talks with Russia to produce COVID-19 vaccine

Green Cross in talks with Russia to produce COVID-19 vaccine

Green Cross employees at Hwasun factory (Courtesy of Green Cross)  South Korea’s pharmaceutical company Green Cross Corporation (GC) is holding a series of close meetings on contract manufacturing of Russia’s COVID-19 vaccine CoviVac, according to industry sources on Mar. 17. C
(* comment hide *}